{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:04:21Z","timestamp":1794877461798,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13507-3","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:09:01Z","timestamp":1737590941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Baseline [18F]FDG PET\/CT radiomics for predicting interim efficacy in follicular lymphoma treated with first-line R-CHOP"],"prefix":"10.1186","volume":"25","author":[{"given":"Zeying","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"5","key":"13507_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.crad.2010.01.010","volume":"65","author":"D Hayashi","year":"2010","unstructured":"Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-C\u00e9ligny P, et al. Follicular non-Hodgkin\u2019s lymphoma. Clin Radiol. 2010;65(5):408\u201320.","journal-title":"Clin Radiol"},{"issue":"1","key":"13507_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, L\u00f3pez-Guillermo A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;5(1):83.","journal-title":"Nat Rev Dis Primers"},{"key":"13507_CR3","unstructured":"Cahill KE, Smith SM. Follicular Lymphoma: a Focus on Current and Emerging Therapies. Oncology (Williston Park). 2022;36(2):97\u2212106."},{"issue":"3","key":"13507_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.19213","volume":"204","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, et al. R-CHOP treatment for patients with advanced follicular lymphoma: over 15-year follow-up of JCOG0203. Br J Haematol. 2024;204(3):849\u201360.","journal-title":"Br J Haematol"},{"issue":"12","key":"13507_CR5","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638\u201351.","journal-title":"Am J Hematol"},{"issue":"12","key":"13507_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11912-021-01126-7","volume":"23","author":"D Wallace","year":"2021","unstructured":"Wallace D, Casulo C. Early progressing Follicular Lymphoma. Curr Oncol Rep. 2021;23(12):149.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"13507_CR7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2016.67.4879","volume":"34","author":"C Casulo","year":"2016","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare. Study J Clin Oncol. 2016;34(12):1430.","journal-title":"Study J Clin Oncol"},{"issue":"4","key":"13507_CR8","first-page":"661","volume":"41","author":"ME Phelps","year":"2000","unstructured":"Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41(4):661\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"13507_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-016-0399-z","volume":"17","author":"G Thanarajasingam","year":"2016","unstructured":"Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in staging, response evaluation, and surveillance of lymphoma. Curr Treat Options Oncol. 2016;17(5):24.","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"13507_CR10","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Le Dortz","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"13507_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.medcli.2021.03.041","volume":"157","author":"P Mozas","year":"2021","unstructured":"Mozas P, Sorigu\u00e9 M, L\u00f3pez-Guillermo A. Actualizaci\u00f3n en El diagn\u00f3stico,pron\u00f3stico y tratamiento del linfoma folicular. Med Clin(Barc). 2021;157(9):440\u20138.","journal-title":"Med Clin(Barc)"},{"issue":"5","key":"13507_CR12","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1097\/HS9.0000000000000861","volume":"7","author":"C Rodier","year":"2023","unstructured":"Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, et al. Risk factors of progression in low-tumor burden follicular lymphoma initially managed by watch and wait in the era of PET and Rituximab. HemaSphere. 2023;7(5):e861.","journal-title":"HemaSphere"},{"issue":"3","key":"13507_CR13","first-page":"202","volume":"41","author":"A D\u00edaz-Silv\u00e1n","year":"2022","unstructured":"D\u00edaz-Silv\u00e1n A, Ot\u00f3n-S\u00e1nchez LF, Caresia-Ar\u00f3ztegui AP, Del Puig C\u00f3zar-Santiago M, Orcajo-Rinc\u00f3n J, de Arcocha-Torres M, et al. Clinical application of [18F]FDG PET\/CT in follicular lymphoma. Rev Esp Med Nucl Imagen Mol(Engl Ed). 2022;41(3):202\u201312.","journal-title":"Rev Esp Med Nucl Imagen Mol(Engl Ed)"},{"key":"13507_CR14","doi-asserted-by":"publisher","first-page":"943151","DOI":"10.3389\/fonc.2022.943151","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Wang M, Zhang Y, Hu F, Wang K, Wang C, et al. Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET\/CT. Front Oncol. 2022;12:943151.","journal-title":"Front Oncol"},{"issue":"11","key":"13507_CR15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood.2020008243","volume":"139","author":"J Trotman","year":"2022","unstructured":"Trotman J, Pettitt AR. Is it time for PET-guided therapy in follicular lymphoma? Blood. 2022;139(11):1631\u201341.","journal-title":"Blood"},{"issue":"1","key":"13507_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12935-021-02094-5","volume":"21","author":"M Xie","year":"2021","unstructured":"Xie M, Wang L, Jiang Q, Luo X, Zhao X, Li X, et al. Significance of initial, interim and end-of-therapy 18F-FDG PET\/CT for predicting transformation risk in follicular lymphoma. Cancer Cell Int. 2021;21(1):394.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"13507_CR17","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1097\/HS9.0000000000000826","volume":"7","author":"RW Merryman","year":"2023","unstructured":"Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, et al. Interim positron emission tomography during frontline chemoimmunotherapy for follicular lymphoma. Hemasphere. 2023;7(2):e826.","journal-title":"Hemasphere"},{"issue":"3","key":"13507_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.semnuclmed.2022.10.004","volume":"53","author":"MN Zeman","year":"2023","unstructured":"Zeman MN, Akin EA, Merryman RW, Jacene HA. Interim FDG-PET\/CT for response assessment of lymphoma. Semin Nucl Med. 2023;53(3):371\u201388.","journal-title":"Semin Nucl Med"},{"key":"13507_CR19","doi-asserted-by":"crossref","unstructured":"Boo SH, O JH, Kwon SJ, Yoo IR, Kim SH, Park GS, et al. Predictive value of interim and end-of-therapy 18F-FDG PET\/CT in patients with follicular lymphoma. Nucl Med Mol Imaging. 2019;53(4):263\u20139.","DOI":"10.1007\/s13139-019-00602-0"},{"issue":"3","key":"13507_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/RLU.0000000000004060","volume":"47","author":"JE Jimenez","year":"2022","unstructured":"Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, et al. Lesion-based radiomics signature in pretherapy 18F-FDG PET predicts treatment response to Ibrutinib in lymphoma. Clin Nucl Med. 2022;47(3):209\u201318.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"13507_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10147-019-01482-2","volume":"24","author":"M Tatsumi","year":"2019","unstructured":"Tatsumi M, Isohashi K, Matsunaga K, Watabe T, Kato H, Kanakura Y, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24(10):1292\u2013300.","journal-title":"Int J Clin Oncol"},{"key":"13507_CR22","doi-asserted-by":"publisher","first-page":"6347404","DOI":"10.1155\/2021\/6347404","volume":"2021","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhu Y, Chen Z, Li J, Sang S, Deng S. Radiomic features of 18F-FDG PET in Hodgkin lymphoma are predictive of outcomes. Contrast Media Mol Imaging. 2021;2021:6347404.","journal-title":"Contrast Media Mol Imaging"},{"issue":"5","key":"13507_CR23","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00259-021-05626-3","volume":"49","author":"FM De Jesus","year":"2022","unstructured":"De Jesus FM, Yin Y, Mantzorou-Kyriaki E, Kahle XU, de Haas RJ, Yakar D, et al. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET\/CT features. Eur J Nucl Med Mol Imaging. 2022;49(5):1535\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"13507_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-023-00799-2","volume":"20","author":"JP Alderuccio","year":"2023","unstructured":"Alderuccio JP, Kuker RA, Yang F, Moskowitz CH. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime. Nat Rev Clin Oncol. 2023;20(9):640\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"13507_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11307-022-01703-7","volume":"24","author":"H Jiang","year":"2022","unstructured":"Jiang H, Li A, Ji Z, Tian M, Zhang H. Role of radiomics-based baseline PET\/CT imaging in lymphoma: diagnosis, prognosis, and response assessment. Mol Imaging Biol. 2022;24(4):537\u201349.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"13507_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12149-018-1260-1","volume":"32","author":"A Parvez","year":"2018","unstructured":"Parvez A, Tau N, Hussey D, Maganti M, Metser U. 18F-FDG PET\/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin\u2019s lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32(6):410\u20136.","journal-title":"Ann Nucl Med"},{"key":"13507_CR27","doi-asserted-by":"crossref","unstructured":"Eertink JJ, Zwezerijnen GJ, Heymans MW, Pieplenbosch S, Wiegers SE, D\u00fchrsen U, et al. External validation shows that baseline PET radiomics outperform the IPI risk score for prediction of outcome in DLBCL. Blood. 2023;141(25):3055\u201364.","DOI":"10.1182\/blood.2022018558"},{"issue":"1","key":"13507_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13550-023-01047-5","volume":"13","author":"F Jing","year":"2023","unstructured":"Jing F, Liu Y, Zhao X, Pieplenbosch S, Wiegers SE, D\u00fchrsen U, et al. Baseline 18F-FDG PET\/CT radiomics for prognosis prediction in diffuse large B cell lymphoma. EJNMMI Res. 2023;13(1):92.","journal-title":"EJNMMI Res"},{"issue":"2","key":"13507_CR29","doi-asserted-by":"publisher","first-page":"e3266","DOI":"10.1002\/hon.3266","volume":"42","author":"D Albano","year":"2024","unstructured":"Albano D, Calabr\u00f2 A, Dondi F, Bagnasco S, Tucci A, Bertagna F. The role of baseline 2-[18F]\u2010FDG\u2010PET\/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis. Hematol Oncol. 2024;42(2):e3266.","journal-title":"Hematol Oncol"},{"issue":"8","key":"13507_CR30","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/j.acra.2019.10.015","volume":"27","author":"KH Lue","year":"2020","unstructured":"Lue KH, Wu YF, Liu SH, Hsieh TC, Chuang KS, Lin HH, et al. Intratumor heterogeneity assessed by 18F-FDG PET\/CT predicts treatment response and survival outcomes in patients with Hodgkin lymphoma. Acad Radiol. 2020;27(8):e183\u201392.","journal-title":"Acad Radiol"},{"issue":"1","key":"13507_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13550-023-01022-0","volume":"13","author":"R Samimi","year":"2023","unstructured":"Samimi R, Shiri I, Ahmadyar Y, van den Hoff J, Kamali-Asl A, Rezaee A, et al. Radiomics predictive modeling from dual-time-point FDG PET Ki parametric maps: application to chemotherapy response in lymphoma. EJNMMI Res. 2023;13(1):70.","journal-title":"EJNMMI Res"},{"key":"13507_CR32","doi-asserted-by":"publisher","unstructured":"Abdollahi H, Chin E, Clark H, Hyde DE, Thomas S, Wu J, et al. Radiomics-guided radiation therapy: opportunities and challenges. Phys Med Biol. 2022;67(12). https:\/\/doi.org\/10.1088\/1361-6560\/ac6fab.","DOI":"10.1088\/1361-6560\/ac6fab"},{"issue":"27","key":"13507_CR33","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"13507_CR34","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"1","key":"13507_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/10428194.2013.802784","volume":"55","author":"M Meignan","year":"2014","unstructured":"Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France,3\u20135 October 2012. Leuk Lymphoma. 2014;55(1):31\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"13507_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"13507_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s12185-022-03418-5","volume":"116","author":"W Kuroki","year":"2022","unstructured":"Kuroki W, Kitadate A, Ishiyama K, Kameoka Y, Takahashi N. High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma. Int J Hematol. 2022;116(5):712\u201322.","journal-title":"Int J Hematol"},{"issue":"8","key":"13507_CR38","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1007\/s00330-022-08624-7","volume":"32","author":"Q Yang","year":"2022","unstructured":"Yang Q, Luo Y, Zhang Y, Zhang W, Zhou D, Li F. Baseline [18F]FDG PET\/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial watch-and-wait approach. Eur Radiol. 2022;32(8):5568\u201376.","journal-title":"Eur Radiol"},{"issue":"4","key":"13507_CR39","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.4143\/crt.2018.649","volume":"51","author":"JH Liang","year":"2019","unstructured":"Liang JH, Zhang YP, Xia J, Ding CY, Wu W, Wang L, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019;51(4):1479\u201387.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"13507_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12880-023-01138-8","volume":"23","author":"J Dang","year":"2023","unstructured":"Dang J, Peng X, Wu P, Yao Y, Tan X, Ye Z, et al. Predictive value of Dmax and %\u2206SUVmax of 18F-FDG PET\/CT for the prognosis of patients with diffuse large B-cell lymphoma. BMC Med Imaging. 2023;23(1):173.","journal-title":"BMC Med Imaging"},{"issue":"9","key":"13507_CR41","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.3390\/cancers15092494","volume":"15","author":"D Albano","year":"2023","unstructured":"Albano D, Treglia G, Dondi F, Calabr\u00f2 A, Rizzo A, Annunziata S, et al. 18F-FDG PET\/CT maximum tumor dissemination (Dmax) in lymphoma: a New Prognostic. Factor? Cancers. 2023;15(9):2494.","journal-title":"Factor? Cancers"},{"issue":"3","key":"13507_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-020-02910-0","volume":"112","author":"Y Kawaguchi","year":"2020","unstructured":"Kawaguchi Y, Saito B, Nakata A, Matsui T, Sasaki Y, Shimada S, et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy. Int J Hematol. 2020;112(3):341\u20138.","journal-title":"Int J Hematol"},{"issue":"1","key":"13507_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12959-022-00381-3","volume":"20","author":"V Otasevic","year":"2022","unstructured":"Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K, et al. Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J. 2022;20(1):20.","journal-title":"Thromb J"},{"issue":"3","key":"13507_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5045\/br.2014.49.3.148","volume":"49","author":"C Yoo","year":"2014","unstructured":"Yoo C, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res. 2014;49(3):148\u201353.","journal-title":"Blood Res"},{"issue":"1","key":"13507_CR45","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/hon.70010","volume":"43","author":"A Zduniak","year":"2025","unstructured":"Zduniak A, L\u00e9v\u00eaque E, Draye-Carbonnier S, Becker S, Tonnelet D, Dubois S, et al. Combining total metabolic tumor volume with Beta-2-Microglobulin levels predicts outcomes in high-burden follicular lymphoma patients. Hematol Oncol. 2025;43(1):e70010.","journal-title":"Hematol Oncol"},{"issue":"11","key":"13507_CR46","doi-asserted-by":"publisher","first-page":"e017904","DOI":"10.1136\/bmjopen-2017-017904","volume":"7","author":"SF Lee","year":"2017","unstructured":"Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open. 2017;7(11):e017904. Published 2017 Nov 3.","journal-title":"BMJ Open"},{"issue":"4","key":"13507_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/clpt.2009.254","volume":"87","author":"MM Moore","year":"2010","unstructured":"Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"13507_CR48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073\u201381.","journal-title":"Carcinogenesis"},{"issue":"27","key":"13507_CR49","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.2015.64.3643","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-Cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol. 2015;33(27):3074.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13507_CR50","doi-asserted-by":"publisher","first-page":"e0283694","DOI":"10.1371\/journal.pone.0283694","volume":"18","author":"TW Georgi","year":"2023","unstructured":"Georgi TW, Kurch L, Hasenclever D, Warbey VS, Pike L, Radford J, et al. Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions. PLoS ONE. 2023;18(3):e0283694.","journal-title":"PLoS ONE"},{"issue":"2","key":"13507_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5662\/wjm.v4.i2.109","volume":"4","author":"CF Babbs","year":"2014","unstructured":"Babbs CF. Choosing inclusion criteria that minimize the time and cost of clinical trials. World J Methodol. 2014;4(2):109\u201322.","journal-title":"World J Methodol"},{"issue":"10","key":"13507_CR52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943\u201352.","journal-title":"Lancet Oncol"},{"key":"13507_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-8722-2-14","volume":"2","author":"G Siddhartha","year":"2009","unstructured":"Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol. 2009;2:14.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"13507_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"13507_CR55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MNM.0000000000001324","volume":"42","author":"F Tutino","year":"2021","unstructured":"Tutino F, Puccini G, Linguanti F, Puccini B, Rigacci L, Kovalchuk S, et al. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms. Nucl Med Commun. 2021;42(3):284\u201391.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"13507_CR56","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2967\/jnumed.121.263067","volume":"63","author":"J Driessen","year":"2022","unstructured":"Driessen J, Zwezerijnen GJC, Sch\u00f6der H, Drees EEE, Kersten MJ, Moskowitz AJ, et al. The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination Radiomics in 18F-FDG PET scans of patients with classical Hodgkin Lymphoma. J Nucl Med. 2022;63(9):1424\u201330.","journal-title":"J Nucl Med"},{"issue":"3","key":"13507_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-Cell lymphoma: which method is most successful? A study on behalf of the PETRA Consortium. J Nucl Med. 2021;62(3):332\u20137.","journal-title":"J Nucl Med"},{"issue":"2","key":"13507_CR58","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/mp.13322","volume":"46","author":"E Pfaehler","year":"2019","unstructured":"Pfaehler E, Beukinga RJ, de Jong JR, Slart RHJA, Slump CH, Dierckx RAJO, et al. Repeatability of 18 F-FDG PET radiomic features: a phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method. Med Phys. 2019;46(2):665\u201378.","journal-title":"Med Phys"},{"issue":"3","key":"13507_CR59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00259-004-1566-1","volume":"32","author":"NC Krak","year":"2005","unstructured":"Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32(3):294\u2013301.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13507-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:59:30Z","timestamp":1737633570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13507-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13507"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13507-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study was approved by the Ethics Committee of Henan Cancer Hospital (No.2023-KY-0150-001) and was conducted in accordance with the Declaration of Helsinki. Informed consent was waived by Ethics Committee of Henan Cancer Hospital because of retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}